GeoVax Labs (GOVX) 10-K 24 Mar 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 23, 2020	Jun. 30, 2019
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		13,791,601
Entity Public Float			$ 416,380
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(g) Security	Common Stock $.001 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 283,341	$ 259,701
Grant funds and other receivables	68,603	121,814
Prepaid expenses and other current assets	95,320	238,189
Total current assets	447,264	619,704
Property and equipment, net (Note 3)	10,606	11,350
Deposits	11,010	11,010
Total assets	468,880	642,064
Current liabilities:
Accounts payable	152,653	125,859
Accrued expenses (Note 4)	1,851,040	1,238,552
Current portion of notes payable (Note 5)	12,500	260,420
Total current liabilities	2,016,193	1,624,831
Note payable, net of current portion (Note 5)	27,243	39,580
Total liabilities	2,043,436	1,664,411
Commitments (Note 6)
Stockholders’ equity (deficiency):
Preferred stock, $.01 par value (Note 7): Authorized shares – 10,000,000 Issued and outstanding shares – 2,486 and 3,450 at December 31, 2019 and 2018, respectively	1,932,433	1,971,333
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 299,835 and 219 at December 31, 2019 and 2018, respectively	300
Additional paid-in capital	39,340,224	37,483,204
Accumulated deficit	(42,847,513)	(40,476,884)
Total stockholders’ equity (deficiency)	(1,574,556)	(1,022,347)
Total liabilities and stockholders’ equity (deficiency)	$ 468,880	$ 642,064

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	2,486	3,450
Preferred stock, outstanding (in shares)	2,486	3,450
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	600,000,000	600,000,000
Common stock, issued (in shares)	299,835	219
Common stock, outstanding (in shares)	299,835	219

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Grant and collaboration revenue	$ 1,175,896	$ 963,203
Operating expenses:
Research and development	1,910,715	1,878,652
General and administrative	1,637,674	1,647,268
Total operating expenses	3,548,389	3,525,920
Loss from operations	(2,372,493)	(2,562,717)
Other income (expense):
Interest income	6,359	5,213
Interest expense	(4,495)	(2,590)
Total other income (expense)	1,864	2,623
Net loss	$ (2,370,629)	$ (2,560,094)
Basic and diluted:
Loss per common share (in dollars per share)	$ (39.25)	$ (15,610.33)
Weighted average shares outstanding (in shares)	60,402	164

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficiency) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	3,670	107
Balance at Dec. 31, 2017	$ 1,899,085		$ 35,696,648	$ (37,916,790)	$ (321,057)
Sale of convertible preferred stock for cash (in shares)	1,200
Sale of convertible preferred stock for cash	$ 1,190,000				1,190,000
Conversion of preferred stock to common stock (in shares)	(1,420)	95
Conversion of preferred stock to common stock	$ (1,117,752)		1,117,752
Issuance of common stock for services (in shares)		17			17
Issuance of common stock for services			513,500		$ 513,500
Stock-based compensation expense			155,304		155,304
Net loss				(2,560,094)	(2,560,094)
Balance (in shares) at Dec. 31, 2018	3,450	219
Balance at Dec. 31, 2018	$ 1,971,333		37,483,204	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash (in shares)	1,700
Sale of convertible preferred stock for cash	$ 1,542,950		147,050		1,690,000
Conversion of preferred stock to common stock (in shares)	(2,664)	296,390
Conversion of preferred stock to common stock	$ (1,581,850)	$ 296	1,581,554
Issuance of common stock for services (in shares)		3,224			3,224
Issuance of common stock for services		$ 3	23,997		$ 24,000
Stock-based compensation expense			104,420		104,420
Net loss				(2,370,629)	(2,370,629)
Adjustments and rounding for reverse stock split (in shares)		2
Adjustments and rounding for reverse stock split		$ 1	(1)
Balance (in shares) at Dec. 31, 2019	2,486	299,835
Balance at Dec. 31, 2019	$ 1,932,433	$ 300	$ 39,340,224	$ (42,847,513)	$ (1,574,556)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (2,370,629)	$ (2,560,094)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8,350	19,801
Stock-based compensation expense	327,500	469,724
Changes in assets and liabilities:
Grant funds and other receivables	53,211	(62,056)
Prepaid expenses and other current assets	(56,211)	36,480
Accounts payable and accrued expenses	639,282	553,119
Total adjustments	972,132	1,017,068
Net cash used in operating activities	(1,398,497)	(1,543,026)
Cash flows from investing activities:
Purchase of property and equipment	(7,606)
Net cash used in investing activities	(7,606)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	1,440,000	1,190,000
Proceeds from issuance of notes payable		300,000
Principal repayment of notes payable	(10,257)
Net cash provided by financing activities	1,429,743	1,490,000
Net increase (decrease) in cash and cash equivalents	23,640	(53,026)
Cash and cash equivalents at beginning of period	259,701	312,727
Cash and cash equivalents at end of period	$ 283,341	$ 259,701

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Common stock issued (in shares)	296,390	95
Conversion from Notes Payable to Convertible Preferred Stock [Member]
Notes payable cancelled in exchange for convertible preferred stock	$ 250,000
Conversion of Preferred Stock into Common Stock [Member]
Preferred stock converted (in shares)	2,664	1,420
Common stock issued (in shares)	296,390	95

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector. Our current development programs are focused on preventive vaccines against coronavirus (COVID- 19 Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We aim to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiaries, GeoVax, Inc. and Immutak Oncology, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation As described in Notes 7 11, April 30, 2019, one five hundred January 21, 2020, one two thousand The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources and government and other collaborative funding commitments will be sufficient to continue our planned operations into the second 2020. not may not Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 not 12 12 2016 02 January 1, 2019; no 12 6 Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 11,157 193 December 31, 2019 2018, 7 December 31, 2019 In July 2017, 2017 11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” 260, 480, 815, 2017 11 2017 11 January 1, 2019; no Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018 2018 2014 09 no Grant revenue – We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds. Research collaborations – We are pursuing a strategy of co-developing or licensing our technology for specific vaccine development approaches and/or disease indications. We have entered into multiple collaborative research and development agreements and have received third 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense. Period - to - Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 7 In May 2017, 2017 09, Scope of Modification Accounting 2017 09” 718, 2017 09 1 2 718 2017 09 January 1, 2018; no In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07 718 2018 07 January 1, 2019; no Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2019 2018: 2019 2018 Laboratory equipment $ 534,577 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 28,685 Total property and equipment 661,918 674,596 Accumulated depreciation and amortization (651,312 ) (663,246 ) Property and equipment, net $ 10,606 $ 11,350 Depreciation expense was $8,350 $19,801 December 31, 2019 2018,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2019 2018: 2019 2018 Accrued management salaries $ 1,323,483 $ 924,509 Accrued directors’ fees 409,219 295,670 Other accrued expenses 118,338 18,373 Total accrued expenses $ 1,851,040 $ 1,238,552

Note 5 - Notes Payable

Note 5 - Notes Payable	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	5 . Notes Payable On February 28, 2018, five $50,000. 5%, second $ 12,500 2020, 2021 2022, $2,243 2023. $2,097 $2,083 December 31, 2019 2018, On December 27, 2018, two $250,000. December 31, 2018. February 2019, 7

Note 6 - Commitments

Note 6 - Commitments	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Commitments Disclosure [Text Block]	6 . Commitments Lease Agreement We lease approximately 8,400 December 31, 2022. December 31, 2019 2018 $161,673 $156,939, $166,155 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of December 31, 2019, $294,000 2020.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	7 . Stockholders’ Equity Preferred Stock Summary 10,000,000 $.01 may one December 31, 2019 2018. $ 1,000 December 31, 2019 2018 December 31, 2019 December 31, 2018 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series C Convertible Preferred Stock - - 2,150 705,238 Series E Convertible Preferred Stock - - 1,200 1,190,000 Series H Convertible Preferred Stock 1,686 1,156,338 - - Series I Convertible Preferred Stock 700 700,000 - - Total 2,486 $ 1,932,433 3,450 $ 1,971,333 Series B Convertible Preferred Stock – $1,000 no not December 31, 2019, 100 $350,000 no December 31, 2019 2018. Series C Convertible Preferred Stock – $1,000 no not 2018, 420 28 January February 2019, 587 39 February 2019, 1,563 Series D Convertible Preferred Stock – May 2017, 1,000 $1,000 $980,000. no not 2018, 67 Series E Convertible Preferred Stock – March 2018, 600 $1,000 $590,000. September 2018, 600 $600,000. no not February 2019, 1,200 Series F Preferred Stock – February 2019, 2,763 no not 2019, 507 191 July 2019, 2,256 Series G Preferred Stock – February 2019, 1,000 $1.0 three no not first February 2019, 500 $250,000 5 $250,000. second third April June 2019, 500 $ 500,000 July 2019, 1,000 Series H Preferred Stock – July 2019, 3,257 no not $15,000 80% ten may, 2019, 1,570 296,160 Series I Preferred Stock – July 2019, 700 $700,000. no not $15,000 80% ten may, 2019, no Common Stock Reverse Stock Split – April 15, 2019, April 30, 2019, one five hundred During 2019 2018 296,390 95 During 2019, 3,224 $24,000 2018, 17 $513,500, $314,419 2018. $199,080 December 31, 2018 2019 Stock Option s We have a stock-based incentive plan pursuant to which our Board of Directors may may not 110% ten three There were no December 31, 2019. April 2019 January 2020, December 31, 2019 2018 We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2019 2018 Weighted average risk-free interest rates N/A 2.79 % Expected dividend yield N/A 0.0 % Expected life of option (yrs) N/A 7.0 Expected volatility N/A 71.34 % Total employee and director stock-based compensation expense recognized in the consolidated statement of operations for the years ended December 31, 2019 2018 $104,420 $155,304, $43,801 $41,998 $60,619 $113,306 December 31, 2019, $99,975 Stock Purchase Warrants The following table summarizes our warrants outstanding as of December 31, 2019: Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48 During 2019, 48 $15,000 All of the outstanding warrants contain anti-dilution and price adjustment provisions, which may, no April 30, 2019 January 21, 2020 11

Note 8 - Retirement Plan

Note 8 - Retirement Plan	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	8 . Retirement Plan We participate in a multi-employer defined contribution retirement plan (the “401k third 401k December 31, 2019 2018 401k $25,876 $23,354,

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9 . Income Taxes At December 31, 2019, $65.7 $62.6 2020 2037. $1.1 2022 2039 No 382 may may Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2019 2018: 2019 2018 Deferred tax assets: Net operating loss carryforward $ 15,328,336 $ 16,681,908 Research and development tax credit carryforward 1,122,536 1,063,877 Stock-based compensation expense 1,877,284 1,808,509 Accrued salaries and directors’ fees 450,503 315,246 Depreciation 8,571 8,414 Total deferred tax assets 18,787,230 19,879,954 Deferred tax liabilities - - Net deferred tax assets 18,787,230 19,879,954 Valuation allowance (18,787,230 ) (19,879,954 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2019 2018 U.S. federal statutory rate applied to pretax loss $ (497,833 ) $ (537,620 ) Permanent differences 278 549 Research and development credits (47,053 ) (53,884 ) Change in valuation allowance 544,308 590,955 Reported income tax expense $ -0- $ -0-

Note 10 - Grants and Collaborat

Note 10 - Grants and Collaboration Revenue	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Government Grants and Contracts [Text Block]	10 . Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During 2019 2018, $983,682 $934,575, December 31, 2019, $1,605,505 2020. During 2019 2018, $192,214 $28,628, third

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 1 . Subsequent Event s Reverse Stock Split Following approval by our shareholders at a meeting held on January 3, 2020, January 21, 2020, one two thousand Conversions of Preferred Stock to Common Stock During the first 2020 March 23), 1,686 700 13,481,349 Issuance of Series J P referred Stock On January 24, 2020, 300 $300,000. Our Series J Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series J Preferred Stock has no not $2.00 80% ten may,

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC. SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS For t he Years Ended December 3 1, 201 9 and 201 8 Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2019 $ 19,879,954 $ (1,092,724 ) $ -0- $ -0- $ 18,787,230 Year ended December 31, 2018 19,123,959 755,995 -0- -0- 19,879,954

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiaries, GeoVax, Inc. and Immutak Oncology, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation As described in Notes 7 11, April 30, 2019, one five hundred January 21, 2020, one two thousand The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources and government and other collaborative funding commitments will be sufficient to continue our planned operations into the second 2020. not may not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 not 12 12 2016 02 January 1, 2019; no 12 6
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
Accrued Liabilities [Policy Text Block]	Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 11,157 193 December 31, 2019 2018, 7 December 31, 2019 In July 2017, 2017 11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” 260, 480, 815, 2017 11 2017 11 January 1, 2019; no
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018 2018 2014 09 no Grant revenue – We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds. Research collaborations – We are pursuing a strategy of co-developing or licensing our technology for specific vaccine development approaches and/or disease indications. We have entered into multiple collaborative research and development agreements and have received third 2014 09
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.
Reclassification, Policy [Policy Text Block]	Period - to - Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 7 In May 2017, 2017 09, Scope of Modification Accounting 2017 09” 718, 2017 09 1 2 718 2017 09 January 1, 2018; no In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07 718 2018 07 January 1, 2019; no
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recent Accounting Pronouncements Except as discussed above, there have been no not

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	2019 2018 Laboratory equipment $ 534,577 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 28,685 Total property and equipment 661,918 674,596 Accumulated depreciation and amortization (651,312 ) (663,246 ) Property and equipment, net $ 10,606 $ 11,350

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2019 2018 Accrued management salaries $ 1,323,483 $ 924,509 Accrued directors’ fees 409,219 295,670 Other accrued expenses 118,338 18,373 Total accrued expenses $ 1,851,040 $ 1,238,552

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Preferred Stock [Table Text Block]	December 31, 2019 December 31, 2018 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series C Convertible Preferred Stock - - 2,150 705,238 Series E Convertible Preferred Stock - - 1,200 1,190,000 Series H Convertible Preferred Stock 1,686 1,156,338 - - Series I Convertible Preferred Stock 700 700,000 - - Total 2,486 $ 1,932,433 3,450 $ 1,971,333
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2019 2018 Weighted average risk-free interest rates N/A 2.79 % Expected dividend yield N/A 0.0 % Expected life of option (yrs) N/A 7.0 Expected volatility N/A 71.34 %
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Expiration Date Exercise Price Number of Warrants Series G September 2021 $ 25,440 48 Series H December 2021 1.15 217,392 Series I Aug-Dec 2024 15,000 48

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2019 2018 Deferred tax assets: Net operating loss carryforward $ 15,328,336 $ 16,681,908 Research and development tax credit carryforward 1,122,536 1,063,877 Stock-based compensation expense 1,877,284 1,808,509 Accrued salaries and directors’ fees 450,503 315,246 Depreciation 8,571 8,414 Total deferred tax assets 18,787,230 19,879,954 Deferred tax liabilities - - Net deferred tax assets 18,787,230 19,879,954 Valuation allowance (18,787,230 ) (19,879,954 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2019 2018 U.S. federal statutory rate applied to pretax loss $ (497,833 ) $ (537,620 ) Permanent differences 278 549 Research and development credits (47,053 ) (53,884 ) Change in valuation allowance 544,308 590,955 Reported income tax expense $ -0- $ -0-

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2019 $ 19,879,954 $ (1,092,724 ) $ -0- $ -0- $ 18,787,230 Year ended December 31, 2018 19,123,959 755,995 -0- -0- 19,879,954

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Jan. 21, 2020	Apr. 30, 2019	Dec. 31, 2019shares	Dec. 31, 2018shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount			11,157	193
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		500
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2,000

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 8,350	$ 19,801

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 661,918	$ 674,596
Accumulated depreciation and amortization	(651,312)	(663,246)
Property and equipment, net	10,606	11,350
Laboratory Equipment [Member]
Property and equipment, gross	534,577	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 11,736	$ 28,685

Note 4 - Accrued Expenses - Sch

Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Accrued management salaries	$ 1,323,483	$ 924,509
Accrued directors’ fees	409,219	295,670
Other accrued expenses	118,338	18,373
Total accrued expenses	$ 1,851,040	$ 1,238,552

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual) - USD ($)	Feb. 28, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 27, 2018
Proceeds from Notes Payable, Total			$ 300,000
Interest Expense, Total		4,495	2,590
Term Notes [Member]
Debt Instrument, Face Amount				$ 250,000
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Two		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Three		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four		2,243
Interest Expense, Total		$ 2,097	$ 2,083

Note 6 - Commitments (Details T

Note 6 - Commitments (Details Textual)	12 Months Ended
	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)
Area of Real Estate Property | ft²	8,400
Operating Leases, Rent Expense, Total	$ 161,673	$ 156,939
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	166,155
Lessee, Operating Lease, Liability, Payments, Due Year Two	171,213
Lessee, Operating Lease, Liability, Payments, Due Year Three	176,356
Unrecorded Unconditional Purchase Obligation, Total	$ 294,000

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity (Details Textual) - USD ($)	Jul. 24, 2019	Jul. 16, 2019	Jun. 19, 2019	Apr. 26, 2019	Feb. 26, 2019	Feb. 25, 2019	Feb. 18, 2019	Jul. 31, 2019	Feb. 28, 2019	Sep. 30, 2018	Mar. 31, 2018	May 31, 2017	Feb. 28, 2019	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized														10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share														$ 0.01	$ 0.01
Preferred Stock, Shares Outstanding, Ending Balance														2,486	3,450
Conversion of Stock, Shares Issued														296,390	95
Stock Issued During Period, Shares, Issued for Services														3,224	17
Stock Issued During Period, Value, Issued for Services														$ 24,000	$ 513,500
Stock Issued During Period, Value Expensed During the Period, Issued for Services															314,419
Prepaid Expense, Value of Stock Issued for Services During Period														$ 199,080
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent														110.00%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total														$ 99,975
Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights														48
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 15,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense														$ 104,420	155,304
Share-based Payment Arrangement, Option [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Expense														43,801	41,998
Share-based Payment Arrangement, Option [Member] | General and Administrative Expense [Member]
Share-based Payment Arrangement, Expense														$ 60,619	$ 113,306
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized						1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum			$ 500,000	$ 500,000	$ 250,000	$ 1,000,000
Convertible Preferred Stock and Related Warrants Issued			500	500	500
Series I Convertible Preferred Stock [Member]
Convertible Preferred Stock and Related Warrants Issued			500
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted													587		420
Conversion of Stock, Shares Issued													39		28
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted									1,563
Conversion of Series D Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued															67
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of Stock, Shares Converted									1,200
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted														507
Conversion of Stock, Shares Issued														191
Conversion from Series F Preferred Stock to Series H Preferred Stock [Member]
Conversion of Stock, Shares Converted								2,256
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted														1,570
Conversion of Stock, Shares Issued														296,160
Conversion of Series I Preferred Stock [Member]
Conversion of Stock, Shares Converted														0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share														$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance														100	100
Convertible Preferred Stock, Conversion Price1														$ 350,000
Series D Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share												$ 1,000
Stock Issued During Period, Shares, New Issues												1,000
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost												$ 980,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share											$ 1,000			$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance															1,200
Stock Issued During Period, Shares, New Issues										600	600
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost										$ 600,000	$ 590,000
Series F Convertible Preferred Stock [Member]
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock							2,763
Series G Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance								1,000
Series H Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share														$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance														1,686
Convertible Preferred Stock, Conversion Price1		$ 15,000
Conversion of Stock, Shares Issued		3,257
Series I Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share														$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance														700
Convertible Preferred Stock, Conversion Price1	$ 15,000
Stock Issued During Period, Shares, New Issues	700
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 700,000
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share														$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance															2,150

Note 7 - Stockholders' Equity -

Note 7 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, outstanding (in shares)	2,486	3,450
Preferred Stock	$ 1,932,433	$ 1,971,333
Series B Convertible Preferred Stock [Member]
Preferred stock, outstanding (in shares)	100	100
Preferred Stock	$ 76,095	$ 76,095
Series C Convertible Preferred Stock [Member]
Preferred stock, outstanding (in shares)		2,150
Preferred Stock		$ 705,238
Series E Convertible Preferred Stock [Member]
Preferred stock, outstanding (in shares)		1,200
Preferred Stock		$ 1,190,000
Series H Convertible Preferred Stock [Member]
Preferred stock, outstanding (in shares)	1,686
Preferred Stock	$ 1,156,338
Series I Convertible Preferred Stock [Member]
Preferred stock, outstanding (in shares)	700
Preferred Stock	$ 700,000

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2018
Weighted average risk-free interest rates	2.79%
Expected dividend yield	0.00%
Expected life of option (Year)	7 years
Expected volatility	71.34%

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity - Summary of Warrants (Details)	Dec. 31, 2019$ / sharesshares
Series G Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 25,440
Number of warrants (in shares) | shares	48
Series H Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 1.15
Number of warrants (in shares) | shares	217,392
Series I Warrants [Member]
Exercise price (in dollars per share) | $ / shares	$ 15,000
Number of warrants (in shares) | shares	48

Note 8 - Retirement Plan (Detai

Note 8 - Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 25,876	$ 23,354

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Taxes Paid	$ 0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,100
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	65,700
Operating Loss Carryforwards, Subject to Expiration	$ 62,600

Note 9 - Income Taxes - Deferre

Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforward	$ 15,328,336	$ 16,681,908
Research and development tax credit carryforward	1,122,536	1,063,877
Stock-based compensation expense	1,877,284	1,808,509
Accrued salaries and directors’ fees	450,503	315,246
Depreciation	8,571	8,414
Total deferred tax assets	18,787,230	19,879,954
Deferred tax liabilities
Net deferred tax assets	18,787,230	19,879,954
Valuation allowance	(18,787,230)	(19,879,954)
Net deferred tax asset after reduction for valuation allowance	$ 0	$ 0

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
U.S. federal statutory rate applied to pretax loss	$ (497,833)	$ (537,620)
Permanent differences	278	549
Research and development credits	(47,053)	(53,884)
Change in valuation allowance	544,308	590,955
Reported income tax expense	$ 0	$ 0

Note 10 - Grants and Collabor_2

Note 10 - Grants and Collaboration Revenue (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 1,175,896	$ 963,203
Unused Grant Funds	1,605,505
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	983,682	934,575
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 192,214	$ 28,628

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual)	Jan. 24, 2020USD ($)$ / sharesshares	Jan. 21, 2020	Apr. 30, 2019	Mar. 23, 2020shares	Dec. 31, 2019shares	Dec. 31, 2018shares
Conversion of Stock, Shares Issued					296,390	95
Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted					1,570
Conversion of Stock, Shares Issued					296,160
Subsequent Event [Member] | Series J Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues	300
Proceeds from Issuance of Preferred Stock and Preference Stock | $	$ 300,000
Convertible Preferred Stock, Conversion Price1 | $ / shares	$ 2
Subsequent Event [Member] | Conversion of Series H Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted				1,686
Subsequent Event [Member] | Conversion of Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted				700
Subsequent Event [Member] | Conversion of Series H and Series I Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Issued				13,481,349
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio			500
Reverse Stock Split [Member] | Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		2,000

Schedule II - Valuation and Q_3

Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Balance at Beginning Of Period	$ 19,879,954	$ 19,123,959
Additions Charged to Costs and Expenses	(1,092,724)	755,995
Additions Charged to Other Accounts	0	0
Deductions	0	0
Balance at End Of Period	$ 18,787,230	$ 19,879,954